NEW YORK (360Dx) – Saladax Biomedical said today that it has inked a non-exclusive agreement to license two Alzheimer's diagnostic tests to Siemens Healthineers.
The tests identify the amyloid beta 1-42 and tau biomarkers, two indicators of the early stages of Alzheimer's disease, in cerebrospinal fluid.
Saladax said that under the agreement, it will provide its "proprietary" raw materials, protocols, and intellectual property, and Siemens will commercialize both assays.
Alzheimer’s disease is currently the sixth-leading cause of death in the US and affects nearly 50 million patients worldwide, Saladax said, and added that disease-modifying therapeutics don't exist and drugs scarcely alleviate symptoms.
By identifying the CSF biomarkers sooner, clinicians will be able to identify Alzheimer's more accurately and begin treatment sooner, the firm said.
It added that evidence of early-stage Alzheimer's can only be determined by positron emission tomography imaging equipment, which Siemen's provides, or by the biomarkers provided in the Saladax tests.
Financial and other terms of the deal were not disclosed